Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

PMV Pharmaceuticals, Inc. Director's Dealing 2025

Jan 22, 2025

34350_dirs_2025-01-22_421053d1-be5b-40f7-8ea4-525b8ca8b5bf.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: PMV Pharmaceuticals, Inc. (PMVP)
CIK: 0001699382
Period of Report: 2024-12-03

Reporting Person: Mack David Henry (N/A)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2024-12-03 Common Stock M 91750 $0.53 Acquired 534210 Direct
2025-01-03 Common Stock M 17709 $0.53 Acquired 551919 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2024-12-03 Employee Stock Option (right to buy) $0.53 M 91750 Disposed 2025-05-11 Common Stock (91750) Direct
2025-01-03 Employee Stock Option (right to buy) $0.53 M 17709 Disposed 2025-05-11 Common Stock (17709) Direct

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock 165307 Indirect
Common Stock 147915 Indirect
Common Stock 56978 Indirect

Footnotes

F1: The shares are held of record by the Stinson 2021 Irrevocable Trust. The reporting person disclaims beneficial ownership of these securities except to the extent of any pecuniary interest therein.

F2: The shares are held of record by the Mack/Mulligan 2020 Irrevocable Descendants' Trust. The reporting person disclaims beneficial ownership of these securities except to the extent of any pecuniary interest therein.

F3: The shares are held of record by the Mack/Mulligan 2020 Irrevocable Descendants' Trust. The reporting person disclaims beneficial ownership of these securities except to the extent of any pecuniary interest therein.

F4: The shares subject to the option are fully vested and immediately exercisable.